APPH — Apontis Pharma AG Income Statement
0.000.00%
Last trade - 00:00
- €68.97m
- €48.18m
- €36.96m
- 20
- 19
- 79
- 30
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | GAS | GAS | GAS | GAS | GAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 40 | 39.2 | 51.2 | 55.7 | 37 |
Cost of Revenue | |||||
Gross Profit | 29 | 25 | 33.8 | 35 | 23.2 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 42.3 | 39.9 | 50.5 | 51.9 | 52.1 |
Operating Profit | -2.24 | -0.614 | 0.65 | 3.81 | -15.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.07 | -1.48 | 0.248 | 3.83 | -14.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.39 | -1.18 | -0.745 | 2.69 | -11.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.39 | -1.18 | -0.745 | 2.69 | -11.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.39 | -1.18 | -0.745 | 2.69 | -11.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.282 | -0.13 | 0.198 | 0.271 | -0.904 |
Dividends per Share |